CN110381985A - 干扰素-λ治疗纤维化的医学用途 - Google Patents

干扰素-λ治疗纤维化的医学用途 Download PDF

Info

Publication number
CN110381985A
CN110381985A CN201780077416.5A CN201780077416A CN110381985A CN 110381985 A CN110381985 A CN 110381985A CN 201780077416 A CN201780077416 A CN 201780077416A CN 110381985 A CN110381985 A CN 110381985A
Authority
CN
China
Prior art keywords
ifn
fibrosis
interferon
functional mimetics
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780077416.5A
Other languages
English (en)
Chinese (zh)
Inventor
T·S·约翰逊
B·图玫
J·鲍尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wurui Therapeutic Co Ltd
UCB SA
Original Assignee
Wurui Therapeutic Co Ltd
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wurui Therapeutic Co Ltd, UCB SA filed Critical Wurui Therapeutic Co Ltd
Publication of CN110381985A publication Critical patent/CN110381985A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201780077416.5A 2016-12-20 2017-12-20 干扰素-λ治疗纤维化的医学用途 Pending CN110381985A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1621728.3 2016-12-20
GBGB1621728.3A GB201621728D0 (en) 2016-12-20 2016-12-20 Methods
PCT/EP2017/083949 WO2018115199A1 (en) 2016-12-20 2017-12-20 Medical use of interferon-lambda for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
CN110381985A true CN110381985A (zh) 2019-10-25

Family

ID=58284677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780077416.5A Pending CN110381985A (zh) 2016-12-20 2017-12-20 干扰素-λ治疗纤维化的医学用途

Country Status (13)

Country Link
US (2) US20190374610A1 (https=)
EP (1) EP3558342B1 (https=)
JP (3) JP7609556B2 (https=)
CN (1) CN110381985A (https=)
AR (1) AR110404A1 (https=)
BR (1) BR112019012084A2 (https=)
CA (1) CA3044949A1 (https=)
EA (1) EA201991175A1 (https=)
ES (1) ES3019566T3 (https=)
GB (1) GB201621728D0 (https=)
TW (1) TW201828973A (https=)
UY (1) UY37534A (https=)
WO (1) WO2018115199A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110882381A (zh) * 2019-12-18 2020-03-17 中国人民解放军陆军军医大学第一附属医院 重组IFN-λ1蛋白在制备防治炎症性骨丢失药物中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7674628B2 (ja) 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
EP3375452B1 (en) * 2017-03-16 2025-01-08 Evangelos Andreakos Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder
EP3849592A4 (en) * 2018-08-23 2022-08-24 Exalt Therapeutics, LLC MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING FRAGMENT AND THEIR USES
EP3999101A1 (en) * 2019-07-18 2022-05-25 ENYO Pharma Method for decreasing adverse-effects of interferon
WO2021119749A1 (en) * 2019-12-20 2021-06-24 The Council Of The Queensland Institute Of Medical Research Treatment of gastrointestinal disease
CN114736878B (zh) * 2021-01-07 2024-04-19 秦皇岛摩登狗生物科技有限公司 共表达猪干扰素l3和猪白介素22重组杆状病毒及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075605A2 (en) * 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated interferon variants and methods of use
CN102584979A (zh) * 2011-01-18 2012-07-18 北京凯因科技股份有限公司 PEG化干扰素λ

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
MXPA03009082A (es) 2001-04-06 2004-11-22 Maxygen Holdings Ltd Variantes polipeptidicas de interferon gamma.
EP1551369A4 (en) 2002-08-28 2007-05-09 Intermune Inc COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES
AU2003225670A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003299962A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004105684A2 (en) 2003-05-16 2004-12-09 Intermune, Inc. Combination therapy for proliferative disorders
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20070258946A1 (en) * 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection
WO2005110478A2 (en) 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1991679A2 (fr) 2006-03-08 2008-11-19 Biomethodes Variants de l'interferon- gamma humain (ifngamma)
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
AU2009255994B2 (en) * 2008-06-05 2014-07-17 Bristol-Myers Squibb Company Use of pegylated Type III Interferons for the treatment of hepatitis C
US20110263484A1 (en) 2008-10-13 2011-10-27 Zymogenetics, Inc. Single chain fc type iii interferons and methods of using same
WO2010048468A1 (en) 2008-10-23 2010-04-29 Concert Pharmaceuticals, Inc. Deuterated macrocyclic inhibitors of viral ns3 protease
EP2350124A1 (en) * 2008-11-20 2011-08-03 Zymogenetics, Inc. Il-29 mutants and uses thereof
IT1400236B1 (it) 2010-05-10 2013-05-24 Univ Bari Impiego di composti noti per il trattamento dell'insufficienza renale cronica(irc)
US9678074B2 (en) 2012-03-28 2017-06-13 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Interferon-λ4 (IFNL4) protein, related nucleic acid molecules, and uses thereof
JP7674628B2 (ja) 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075605A2 (en) * 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated interferon variants and methods of use
CN102584979A (zh) * 2011-01-18 2012-07-18 北京凯因科技股份有限公司 PEG化干扰素λ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
范利娟 等: "IL-28B mRNA在小鼠纤维化肺组织内的表达及意义", 《江苏大学学报（医学版）》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110882381A (zh) * 2019-12-18 2020-03-17 中国人民解放军陆军军医大学第一附属医院 重组IFN-λ1蛋白在制备防治炎症性骨丢失药物中的应用

Also Published As

Publication number Publication date
JP7609556B2 (ja) 2025-01-07
GB201621728D0 (en) 2017-02-01
JP2024156844A (ja) 2024-11-06
WO2018115199A1 (en) 2018-06-28
EP3558342B1 (en) 2025-01-29
US20190374610A1 (en) 2019-12-12
BR112019012084A2 (pt) 2019-11-12
US11975046B2 (en) 2024-05-07
UY37534A (es) 2018-09-28
EA201991175A1 (ru) 2019-11-29
TW201828973A (zh) 2018-08-16
EP3558342A1 (en) 2019-10-30
JP2022081677A (ja) 2022-05-31
CA3044949A1 (en) 2018-06-28
US20240000893A1 (en) 2024-01-04
AR110404A1 (es) 2019-03-27
JP2020511415A (ja) 2020-04-16
ES3019566T3 (en) 2025-05-20

Similar Documents

Publication Publication Date Title
US11975046B2 (en) Medical use of interferon-lambda for the treatment of fibrosis
ES2363162T3 (es) Composicones y procedimientos para el tratamiento de trastornos fibróticos.
CN102724993B (zh) 靶向tnf家族受体并拮抗tnf作用的肽、组合物、方法及其用途
US10369198B2 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
US20210121571A1 (en) Methods of reducing aggregation of il-1ra
US12220446B2 (en) Use of upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and polypeptide coded by 45aa-uORF
CN106029101A (zh) 生物材料和其治疗用途
US20080153753A1 (en) Method of treating side effects induced by therapeutic agents
KR20240153552A (ko) 치료용 사이토카인 및 방법
DE112018001364T5 (de) Verwendung von Lambda-Interferonen bei der Behandlung von mit Adipositas zusammenhängenden Störungen und verwandten Erkrankungen
EP4341280A1 (en) Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
Silva-García et al. Anti-inflammatory defense mechanisms of Entamoeba histolytica
CA3020339C (en) Compositions and methods for treating pancreatitis and pain with death receptor agonists
Guo Investigation of the crosstalk of different interferon lambdas and lambda-related cytokines in the JAK/STAT pathway
US20200179433A1 (en) Nucleotide, Polypeptide and Applications Thereof
Moon et al. An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1
CN108601819B (zh) 用死亡受体激动剂改善系统性硬化症
HK40042415A (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
HK1215540B (en) Factor 1 protein for use in treating or preventing diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Brussels

Applicant after: UCB biopharmaceutical Co.,Ltd.

Applicant after: FIVE PRIME THERAPEUTICS, Inc.

Address before: Brussels

Applicant before: UCB BIOPHARMA SPRL

Applicant before: FIVE PRIME THERAPEUTICS, Inc.

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191025

WD01 Invention patent application deemed withdrawn after publication